Table 4 Combined pulmonary adverse events cited in clinical trials.
From: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
| Colorectal Cancer Cetuximab | Control | Non-Small Cell Lung Cancer Cetuximab | Control | Head-Neck Cancer Cetuximab | Control | |
|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Dyspnea/RI | 70 (3.1) | 35 (2.6) | 131 (13.4) † | 62 (9.2) | 87 (8.7) † | 26 (5.0) |
| PE | 3 (0.1) | 0 (0.0) | 32 (3.3) | 16 (2.4) | 0 (0.0) | 0 (0.0) |
| Pneumonia | 2 (0.1) | 0 (0.0) | 4 (0.4) | 1 (1.2) | 13 (1.4) | 4 (0.8) |
| ILD | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cough | 0 (0.0) | 0 (0.0) | 8 (3.4) | 3 (3.6) | 42 (4.5) † | 40 (7.8) |
| Pneumonitis | 1 (0.0) | 0 (0.0) | 17 (1.7) † | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Pleural Effusion | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (0.3) | 0 (0.0) |
| Increased Sputum | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 28 (3.0) † | 34 (6.6) |
| TOTAL: | 76 (3.4) | 35 (2.6) | 192 (19.6) † | 82 (12.2) | 173 (17.9) | 104 (20.2) |